Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Memantine

Memantine

Memantine is a neuroprotective agent used for the treatment of moderate-to-severe Alzheimer's disease.
It works by regulating glutamate, an important neurotransmitter involved in learning and memory.
Memantine may help improve cognitive function and delay the progression of Alzheimer's symptoms.
Researchers can use PubCompare.ai to optimize their Memantine studies by locating the best protocols from literature, preprints, and patents using AI-driven comparissons.
This tool enhances reproducibility and accuracy, providing a seamless research experience for Memantine optimization.

Most cited protocols related to «Memantine»

1
Amyloid PET Imaging in Alzheimer's Disease
Cited 19 times
[18F]AV-45 was studied in a total of 16 HC volunteers and 16 AD patients. Patients with AD had to be greater than 50 years of age and have a probable diagnosis of AD according to the NINCDS-ADRDA, with a Mini-Mental State Examination (MMSE) score between 10 and 24 inclusive. (12 (link), 13 (link)) HC subjects had to be greater than 50 years of age, with no evidence of cognitive impairment by history and psychometric testing, and had to have an MMSE score of ≥ 29. Subjects who showed evidence of any other significant neurodegenerative or psychiatric disease on clinical examination or MRI, or clinically significant medical comorbidities that might pose a safety risk to the subject or interfere with interpretation of the scan were excluded from the study. Patients with AD could be on a stable dose (by investigator judgment: not in titration period, no change in medication being considered) of an acetylcholinesterase inhibitor, memantine, and/or Vitamin E. Patients who had ever participated in an experimental study with a treatment targeting amyloid (e.g., immunotherapy, secretase inhibitor, selective amyloid lowering agents) were excluded. All procedures were approved by the appropriate Institutional Review Board and all participants or an appropriate representative signed informed consent forms, consistent with established criteria (12 (link)).
Similar acquisition protocols were used at the three centers. All subjects received a single IV bolus of approximately 370 MBq or 10 mCi [18F]AV-45 and PET imaging began. Dynamic brain PET images were collected for a period of approximately 90 minutes. The PET scanners employed were GE Advance (PET only, at JHU), GE Discovery LS (PET/CT), at CHC and MEC, and the Discovery ST (PET/CT), at MEC). In addition plasma metabolite analysis was conducted using the method of Hilton, et al (14 (link)). For detailed PET, metabolite analysis and image acquisition procedures see supplementary information.
Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brašić J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M, & Pontecorvo M.J. (2010). In Vivo Imaging of Amyloid Deposition in Alzheimer’s Disease using the Novel Radioligand [18F]AV-45 (Florbetapir F 18). Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 51(6), 913-920.
Publication 2010
Acetylcholinesterase Inhibitors APP protein, human Brain Diagnosis Disorders, Cognitive Ethics Committees, Research Immunotherapy Inclusion Bodies Memantine Mental Disorders Mini Mental State Examination Patients Pharmaceutical Preparations Physical Examination Plasma Radionuclide Imaging Safety Scan, CT PET Secretase Titrimetry Vitamin E Voluntary Workers
2
Dementia Diagnosis in Intellectual Disability
Cited 12 times
Clinical dementia diagnoses were defined as confirmed diagnoses of dementia recorded by clinicians following clinical assessment. All memory assessments were then summarised in anonymised case vignettes by the researchers, without making reference to clinical diagnosis. We also removed reference to treatment with acetylcholinesterase inhibitors and memantine. Case vignettes were also produced for assessments preceding and following the diagnosis of dementia, where available.
The case vignettes were then presented to two raters who worked independently to rate the case by applying diagnostic criteria delineated in ICD-10 and DSM-IV-TR; that is, the raters assigned the case to ‘no dementia’ or ‘dementia’ according to either ICD-10 or DSM-IV-TR criteria (Table 1). Use of the ICD-10 category of ‘tentative dementia’ was also included.
Raters were also asked to make a separate rating based on their clinical judgement and rate the cases as no dementia, ‘cognitive concern’, ‘possible dementia’ or ‘certain dementia’. Cognitive concern was defined as any evidence of deterioration in cognitive function but where this was of recent onset only and where the rater was unable to exclude a physical causation (such as hypothyroidism) or a mental illness causing changes in behaviour or memory (such as depression). Possible dementia was defined as likely dementia (i.e. significant decline over 6 months or more) but where the raters felt the vignette lacked evidence to be certain of a diagnosis and where they would have wanted further information or to offer another appointment to confirm results and symptoms.
Raters were clinicians (psychiatrists and psychologists) working in the fields of Psychiatry of Intellectual Disability or Psychiatry of Older People who were members of a ‘dementia in intellectual disabilities’ special interest group. Raters remained blinded to the patient’s true clinical diagnosis and any treatment received.
After rating each assessment independently, the raters compared outcomes for each assessment. Where there was disagreement between the raters’ outcomes, a discussion ensued, and a consensus was achieved and recorded. For a subset of assessments, the outcome of each individual rater was recorded prior to consensus allowing for determination of inter-rater reliability.
Sheehan R., Sinai A., Bass N., Blatchford P., Bohnen I., Bonell S., Courtenay K., Hassiotis A., Markar T., McCarthy J., Mukherji K., Naeem A., Paschos D., Perez-Achiaga N., Sharma V., Thomas D., Walker Z, & Strydom A. (2014). Dementia diagnostic criteria in Down syndrome. International journal of geriatric psychiatry, 30(8), 857-863.
Publication 2014
Acetylcholinesterase Inhibitors Clinical Reasoning Cognition Diagnosis Feelings Hypothyroidism Intellectual Disability Interest Groups Memantine Memory Mental Disorders Patients Physical Examination Presenile Dementia Psychiatrist
3
Multicenter Study of Progressive Supranuclear Palsy
Cited 11 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Acetylcholinesterase Inhibitors Antipsychotic Agents Dementia Levodopa Lithium Memantine Methylene Blue Mini Mental State Examination Motor Neuron Disease MRI Scans Muscle Rigidity Neuroprotection Ophthalmoplegia Patients Pharmaceutical Preparations Progressive Supranuclear Palsy Quetiapine rasagiline Syndrome ubidecarenone
4
Finnish Alzheimer's Disease Reimbursement Data
Cited 10 times
The Finnish special reimbursement register contains information on reimbursement due to specific chronic diseases such as diabetes, cardiovascular diseases, and Alzheimer’s disease. As per national guidelines for Ad treatment,15 (link) this register allows identification of every person with clinically diagnosed Ad, regardless of whether they purchased the Ad medication after being diagnosed. We are not aware of this kind of nationwide register with longitudinal data elsewhere, although Sweden recently set up the Swedish dementia Registry (SveDem), including 6,937 dementia patients diagnosed during 2007–2009.14 (link)
The Finnish Current Care Guidelines recommend that all persons with Ad are treated with acetylcholinesterase inhibitors or with memantine unless there is a specific contraindication.15 (link) To be eligible for reimbursed Ad medication, the patient needs to have a verified diagnosis of Ad described in a medical statement submitted to the SII by a physician. The medical statement must state that the patient has: (1) symptoms consistent with Ad; (2) experienced a decrease in social capacity over a period of at least 3 months; (3) received a computed tomography/magnetic resonance imaging scan; (4) had possible alternative diagnoses excluded; and (5) received confirmation of the diagnosis by a registered neurologist or geriatrician.15 (link) Ad is diagnosed according to the National Institute of Neurological and Communicative disorders and Stroke and the Alzheimer’s disease and Related disorders Association (NINCDS-ADRDA [now known as the Alzheimer’s Association]) and The Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for Alzheimer’s disease.16 (link),17 The physician also needs to confirm whether the patient has other dementing diseases, such as multi-infarct dementia or Lewy body dementia. However, patients with these diseases are also entitled to reimbursed medicines if the symptoms are considered to be mainly caused by AD.18
The special reimbursements for acetylcholinesterase inhibitors and memantine were introduced in 1999 and 2003, respectively, and the diagnostic criteria have been consistent. In the beginning, the reimbursement decisions were often made on a temporary basis, but permanent decisions were introduced in July 2003. earlier, only patients with mild or moderate Ad were entitled to reimbursed anti-dementia medication, but the reimbursement was not withdrawn if/when the patient developed severe ADs. People with severe Ad have been entitled to reimbursed AD medication since 2003. Thus, our study sample includes persons with all stages of AD. data on severity or stage of Alzheimer’s disease is not available from the registers, but the diagnosis date from the special reimbursement register can be used as a crude estimate on mild/moderate stages of AD. The Finnish public health system covers all residents regardless of age or income. Thus, one of the strengths of our cohort is that, unlike cohorts consisting of members of a particular private health care insurance scheme, MedAlz-2005 is not selected on the basis of socioeconomic position.
Tolppanen A.M., Taipale H., Koponen M., Lavikainen P., Tanskanen A., Tiihonen J, & Hartikainen S. (2013). Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study. Clinical Epidemiology, 5, 277-285.
Publication 2013
Acetylcholinesterase Inhibitors Alzheimer's Disease Alzheimer Disease 16 Cardiovascular Diseases Diabetes Mellitus Diagnosis Disease, Chronic Geriatricians Health Insurance Lewy Body Disease Magnetic Resonance Imaging Memantine Multi-Infarct Dementia Neurologists Patients Pharmaceutical Preparations Physicians Presenile Dementia X-Ray Computed Tomography
5
Comprehensive Neuropsychological Evaluation for Dementia Detection
Cited 9 times
The Modified Mini-Mental State Examination (3MSE)21 (link) was administered at every 6-month visit, as was the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog)22 (link) through August 1, 2004; thereafter, the ADAS-Cog was administered annually in alternation with the all-study annual neuropsychological evaluations, as described below. The Telephone Interview for Cognitive Status23 was administered when in-person visits were missed.
A comprehensive neuropsychological test battery was administered to all participants at study screening and at annual intervals beginning in 2004 (approximately 3-4 years after randomization). In addition to these regularly administered (all-study) neuropsychological evaluations to all participants, diagnostic neuropsychological evaluations (consisting of the same neuropsychological tests) were administered to participants with potential cognitive changes as part of the mechanism for diagnosing dementia, the primary GEM study outcome. Diagnostic neuropsychological evaluations were administered at any visit during the study for the following reasons: (1) specified point decline on 2 of the 3 cognitive screening tests (3MSE, CDR, or ADAS-Cog); (2) onset of a new memory or other cognitive problem reported by the participant or family; (3) new dementia diagnosis by a nonstudy physician; or (4) initiation of a medication with a cognitive indication, such as donepezil, rivastigmine, galantamine, or memantine.
The neuropsychological test battery was designed to assess multiple cognitive domains and be maximally sensitive to detecting cognitive decline associated with preclinical or incident dementia. Memory tests included the California Verbal Learning Test24 and recall conditions of the modified Rey Osterrieth Figure Test.25 (link) Tests of visual-spatial construction included the copy condition of the Rey Osterrieth Figure Test and the modified Wechsler Adult Intelligence Scale–Revised (WAIS-R) Block Design.26 (link) Language tests included a 30-item Boston Naming Test27 (link) and semantic verbal fluency.28 Tests of attention and psychomotor speed included the WAIS-R Digit Span and the Trail Making Test Part A.29 Tests of executive functions included the Trail Making Test Part B29 and Stroop Color/Word Test.30
Snitz B.E., O'Meara E.S., Carlson M.C., Arnold A.M., Ives D.G., Rapp S.R., Saxton J., Lopez O.L., Dunn L.O., Sink K.M, & DeKosky S.T. (2009). Ginkgo biloba for Preventing Cognitive Decline in Older Adults: A Randomized Trial. JAMA : the journal of the American Medical Association, 302(24), 2663-2670.
Publication 2009
Attention Cognition Cognition Disorders Diagnosis Disorders, Cognitive Donepezil Executive Function Fingers Galantamine Language Tests Memantine Memory Mental Recall Mini Mental State Examination Neuropsychological Tests Pharmaceutical Preparations Physicians Presenile Dementia Rivastigmine Stroop Test Vision Tests

Most recents protocols related to «Memantine»

1
Dementia Risk Factors Among Korean Adults
The primary outcome of this study was the incidence of all-cause dementia, including Alzheimer’s disease (AD), vascular dementia (VaD), and other types of dementia (ICD-10 diagnostic codes: F00, F01, F02, F03, G30, or G31). Outcome events were defined when both ICD-10 codes and the prescription records of anti-dementia drugs, including donepezil, galantamine, rivastigmine, and memantine were used. This definition has been widely accepted with high accuracy, having 94.7% positive predictive value in K-NHID21 (link). The secondary outcomes included AD (F00 or G30) and VaD (F01). The date of the second health checkup was defined as the index date, and the participants were followed up until December 31, 2019 or until the development of the primary outcome, whichever came first.
We obtained information from the second general health checkup based on previous studies related to risk factors for dementia. Specifically, we obtained demographic data, including age, sex, height, body weight, and waist circumference, as well as information regarding health-related lifestyles, including smoking status, categorized as a current smoker or not, and alcohol consumption status, categorized as alcohol users (any alcohol consumption) or not. Baseline comorbidities including hypertension, dyslipidemia, diabetes mellitus, and chronic kidney disease were also obtained. The operational definition of covariates and outcomes in cardiovascular research is well documented in several studies based on K-NHID12 (link). CKD was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation. Low-income level was defined when the participants were medical benefit beneficiaries and were included in the lowest quartile of income levels. Further, laboratory data, including levels of random glucose, total cholesterol, glomerular filtration rate, and systolic/diastolic blood pressure, were also obtained at the ambulatory health exam visits after index stroke. Among these variables, age, sex, smoking status, alcohol consumption, income level, history of diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease were used as covariates.
Cheon D.Y., Han K.D., Kim C.H., Oh M.S., Lee B.C., Kim Y., Lee S.H., Kim C., Lim J.S., Lee M, & Yu K.H. (2023). Association between exercise habit changes and incident dementia after ischemic stroke. Scientific Reports, 13, 3959.
Full text: Click here
Publication 2023
Body Weight Cardiovascular System Cerebrovascular Accident Cholesterol Chronic Kidney Diseases Dementia, Vascular Diabetes Mellitus Diagnosis Diastole Donepezil Dyslipidemias Ethanol Galantamine Glomerular Filtration Rate Glucose High Blood Pressures Memantine Pharmaceutical Preparations Presenile Dementia Pressure, Diastolic Rivastigmine Systole Systolic Pressure Waist Circumference
2
Memantine and Baicalein Analysis
Memantine was obtained as a gift sample from Intas Pharmaceuticals (India). Baicalein was procured from the Chemical Centre (Mumbai, India). Aluminum chloride and acetylcholine iodide were purchased from Sigma Aldrich, USA. β-Amyloid antibodies (catalog no. SC-28365, lot no. I0117), and BDNF antibodies (catalog No.: SC-65514, lot no. L0816) were purchased from Santacruz Biotechnology Inc. (USA).
Jadhav R, & Kulkarni Y.A. (2023). Effects of baicalein with memantine on aluminium chloride-induced neurotoxicity in Wistar rats. Frontiers in Pharmacology, 14, 1034620.
Full text: Click here
Publication 2023
Acetylcholine Iodide Aluminum Chloride Amyloid Proteins Antibodies baicalein Memantine Pharmaceutical Preparations
3
Aluminum-Induced Neurodegeneration: Therapeutic Intervention
Rats were randomly divided into six experimental groups, each containing ten rats. Group I animals served as the normal control group, which received distilled water for 42 days. Group II was disease control and received aluminum chloride solution (100 mg/kg) for 42 days. Group III received aluminum chloride solution (100 mg/kg) and memantine (20 mg/kg) orally. Group IV received aluminum chloride solution (100 mg/kg) and baicalein (10 mg/kg) orally. Group V received an oral administration of aluminum chloride solution (100 mg/kg), memantine (20 mg/kg) and baicalein (5 mg/kg). Group VI was administered aluminum chloride solution (100 mg/kg), memantine (20 mg/kg) and baicalein (10 mg/kg) orally for 42 days. The dose of baicalein was selected based on the available literature (Zhou et al., 2016 (link)).
Jadhav R, & Kulkarni Y.A. (2023). Effects of baicalein with memantine on aluminium chloride-induced neurotoxicity in Wistar rats. Frontiers in Pharmacology, 14, 1034620.
Full text: Click here
Publication 2023
Administration, Oral Aluminum Chloride Animals baicalein Memantine Rattus norvegicus
4
Restless Legs Syndrome and Dementia Risk
Chi-square for categorical variables and Mann–Whitney U test for continuous variables due to non-normality were used to compare the baseline characteristics between patients with RLS and RLS-free controls. Cox proportional hazards regression models were applied to explore the association between RLS and the risk of dementia after adjusting for age, sex, income, residence, CCI, and history of other comorbidities. Among the Cox regression models, we used the Fine–Gray subdistribution hazard model with mortality as a competing risk given the old age of the study population. The proportional hazard assumption was satisfied in our Cox model (Schoenfeld individual test p-value > 0.05).
Sensitivity analyses were performed using four different models. In model 1, dementia was defined as the prescription of anti-dementia medications (donepezil, rivastigmine, galantamine, and memantine) at least twice and a diagnosis of the ICD-code of dementia. Although these medications were approved for only AD (rivastigmine additionally for Parkinson’s disease dementia), they can be used for cognitive symptoms in other types of dementia based on recommendations from multiple guidelines [31 (link)–33 (link)]. The previous study revealed that the definition of all-cause dementia by ICD-10 code plus anti-dementia medications had a positive predictive value of 94.7% when reviewing the medical records of 972 patients in two hospitals [34 (link)]. In model 2, medication history was added to the ICD code to define RLS. Patients with RLS ICD-code (G25.8) who had taken dopamine agonists (ropinirole or pramipexole) twice or more were regarded as patients with RLS (n = 1458). In this sensitivity model, we excluded patients with Parkinson’s disease because they could also take dopamine agonists. In model 3, patients taking antipsychotic agents were excluded because the antidopaminergic property of antipsychotic agents could lead to a misdiagnosis of RLS (n = 2482). The following antipsychotic agents approved in South Korea were used in this study: haloperidol, sulpiride, chlorpromazine, perphenazine, pimozide, risperidone, olanzapine, quetiapine, paliperidone, amisulpride, aripiprazole, ziprasidone, clozapine, blonanserin, and zotepine. In model 4, patients with RLS only diagnosed by psychiatrists or neurologists were included (n = 1154) to preclude the possible misdiagnosis by non-expert physicians.
To evaluate the effect of dopamine agonists (pramipexole and ropinirole) on the development of dementia, the risk of dementia was compared after dividing RLS patients by dopamine agonist use. Patients with RLS who were prescribed pramipexole or ropinirole at least once were considered dopamine agonist users. All missing data were addressed using listwise deletion. Data processing and statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at a two-tailed p-value of < 0.05.
Kim K.Y., Kim E.H., Lee M., Ha J., Jung I, & Kim E. (2023). Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study. Alzheimer's Research & Therapy, 15, 46.
Full text: Click here
Publication 2023
Age Groups agonists Amisulpride Antipsychotic Agents Aripiprazole blonanserin Chlorpromazine Clozapine Deletion Mutation Donepezil Dopamine Agonists Dopamine Effect Galantamine Haloperidol Hypersensitivity Memantine Neurobehavioral Manifestations Neurologists Olanzapine Paliperidone Parkinson Disease Patients Perphenazine Pharmaceutical Preparations Physicians Pimozide Pramipexole Prescription Drugs Presenile Dementia Psychiatrist Quetiapine Risperidone Rivastigmine ropinirole Sulpiride ziprasidone zotepine
5
Dementia Care Longitudinal Study
Data originally collected every three months between October 2021 and April 2022 were extracted. Data were originally collected via questionnaires that were responded by proxy, such as facility managers, care managers, nurses, or other caregiving staff at nursing homes at 0 month, 3 months, and 6 months from October 2021(baseline).
The data source included demographics and clinical characteristics of participants, including age, sex, independence in activity of daily living owing to dementia assessed using the “Criteria for determination of the daily life independence level of the elderly with dementia” [19 ], prescribed anti-dementia drugs (i.e., donepezil, galantamine, rivastigmine, memantine, and yokukansan/YiganSan), activities of daily living (ADL) assessed using Barthel Index (BI) [20 ], occupation/position of the proxies who responded to the EQ-5D-5L+C and EQ-5D-5L [2, 6, 14– 17 (link)], EQ-5D-5L+C (proxy version responded by proxy), EQ-5D-5L (proxy version responded by proxy), and MMSE [18 (link)].
Igarashi A., Sakata Y., Azuma-Kasai M., Kamiyama H., Kawaguchi M., Tomita K., Ishii M, & Ikeda M. (2023). Linguistic and Psychometric Validation of the Cognition Bolt-On Version of the Japanese EQ-5D-5L for the Elderly. Journal of Alzheimer's Disease, 91(4), 1447-1458.
Full text: Click here
Publication 2023
Aged Case Manager Donepezil Galantamine Memantine Mini Mental State Examination Nurses Nursing Staff Pharmaceutical Preparations Presenile Dementia Rivastigmine Yi-Gan San

Top products related to «Memantine»

1
Memantine by Merck Group
Sourced in United States, Germany, United Kingdom
Memantine is a laboratory equipment product manufactured by Merck Group. It is a chemical compound used in various research and diagnostic applications. Memantine functions as a N-methyl-D-aspartate (NMDA) receptor antagonist, which can be utilized in scientific investigations and experiments.
2
Memantine by Bio-Techne
Sourced in United Kingdom, France, United States
Memantine is a lab equipment product designed to measure and analyze various biochemical and biological processes. It is a quantitative analytical tool used for research and development purposes in life science and biotechnology applications.
3
Memantine hydrochloride by Merck Group
Sourced in United States
Memantine hydrochloride is a chemical compound used in various research and laboratory applications. It functions as a N-methyl-D-aspartate (NMDA) receptor antagonist, which can be utilized for studying neurological processes and related research areas.
4
Mk 801 by Merck Group
Sourced in United States, Sao Tome and Principe, United Kingdom, Germany, France, Macao, China, Italy, Brazil, Australia
MK-801 is a pharmaceutical compound developed by Merck Group. It is a potent and selective non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. The core function of MK-801 is to block the NMDA receptor, which is involved in various physiological and pathological processes in the central nervous system.
5
Mk 801 by Bio-Techne
Sourced in United Kingdom, United States, Germany, Poland
MK-801 is a laboratory reagent used in scientific research. It is a selective and high-affinity non-competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor. The core function of MK-801 is to inhibit NMDA receptor-mediated responses, which can be used to study the role of NMDA receptors in various biological processes.
6
Memantine hydrochloride by Bio-Techne
Sourced in United Kingdom
Memantine hydrochloride is a chemical compound used in laboratory research. It is a small molecule that functions as an N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine hydrochloride is commonly used in in vitro and in vivo studies to investigate the role of NMDA receptor signaling in various biological processes.
7
Galantamine by Merck Group
Sourced in United States, Germany, Spain, France, China, Japan, United Kingdom
Galantamine is a laboratory equipment product manufactured by Merck Group. It is used as a cognitive enhancer and is primarily used in research settings.
8
Fluo 4 am by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Canada, China, France, Spain, Italy, Sweden, Japan, Switzerland, Belgium, Australia, Austria, Finland, New Zealand
Fluo-4 AM is a fluorescent calcium indicator used for the detection and measurement of intracellular calcium levels. It functions by binding to calcium ions, which results in an increase in fluorescence intensity. This product is commonly used in various cell-based assays and research applications involving calcium signaling.
9
Trolox by Merck Group
Sourced in United States, Germany, Italy, France, Spain, Brazil, India, Poland, Switzerland, Canada, China, New Zealand, United Kingdom, Chile, Macao, Mexico, Australia, Portugal, Czechia, Hungary, Japan, Belgium, Singapore, Argentina, Ireland, Sao Tome and Principe, Denmark, Thailand, Israel, Morocco, Cameroon
Trolox is a water-soluble vitamin E analog that functions as an antioxidant. It is commonly used in research applications as a reference standard for measuring antioxidant capacity.
10
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

More about "Memantine"

Memantine, a neuroprotective agent, is widely used for the treatment of moderate-to-severe Alzheimer's disease.
It works by regulating glutamate, an important neurotransmitter involved in learning and memory.
Memantine hydrochloride, also known as MK-801, can help improve cognitive function and delay the progression of Alzheimer's symptoms.
Researchers can utilize PubCompare.ai, a powerful AI-driven tool, to optimize their Memantine studies by locating the best protocols from literature, preprints, and patents.
This enhances reproducibility and accuracy, providing a seamless research experience for Memantine optimization.
Galantamine, another Alzheimer's medication, and Fluo-4 AM, a calcium indicator, can be used in conjunction with Memantine studies.
Trolox, a vitamin E derivative, and DMSO, a common solvent, may also be relevant in Memantine research.
By leveraging these insights and tools, researchers can egreatly advance their understanding and application of Memantine in the fight against Alzheimer's disease.